A case report: Successful management of pulmonary aspergillosis associated with COVID ‐ 19 ARDS

Abstract

The recent global outbreak of coronavirus disease-19, also known as COVID-19, has infected more than 142 million people worldwide, causing more than 3 million deaths. It has been shown that up to 40% of hospitalized COVID-19 patients may develop ARDS. Although not proven, anti-inflammatory and anti-cytokine treatments are recommended to suppress the cytokine storm that develops in the early stages of the disease. In this case report, a case of pulmonary aspergillus developed as a complication of treatment for ARDS caused by covid 19 in a 50-year-old male patient will be presented in the light of current literature.

Keywords

• covid 19
• ARDS
• Pulmuner Aspergilloz Basarılı Weaning
• Steroid Tedavisi

References

1. Referance 1. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. Wu C., Chen X. et al. JAMA Intern. Med. 2020 doi: 10.1001 /jamainternmed.2020.0994.
2. Referance 2. Dexamethasone in Hospitalized Patients with Covid-19. The RECOVERY Collaborative Group. N Engl J Med 2021;384:693-704. DOI: 10.1056/NEJMoa2021436.
3. Referance 3. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Schauwvlieghe A FAD, Rijnders BJA, Wauters J et al. Dutch-Belgian Mycosis study group. Lancet Respir Med. 2018 Oct; 6(10):782-792. doi: 10.1016/S2213-2600(18)30274-1.
4. Referance 4. Borman, A.M.; Palmer, M.D.; Fraser, M et al. COVID-19 associated invasive aspergillosis: Data from the UK National Mycology Reference Laboratory. J. Clin. Microbiol. 2020. doi: 10.1128/JCM.02136-20.
5. Referance 5. Patterson TF, Thompson GR III, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–60. PubMed. doi: 10.1093/cid/ciw326.